Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02123030 · ClinicalTrials.gov registry record
A Micro/Nano Device for Exhaled Breath Analysis
A clinical trial, sponsored by University of Louisville.
- Completed
- Registry status
- 728
- Enrollment target
NCT02123030: Completed study, sponsored by University of Louisville.
NCT02123030 is a clinical trial that has completed, run by University of Louisville. The registered enrollment target is 728 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02123030 has completed, sponsored by University of Louisville.
- COMPLETED
- Registry status
- 728 participants
- Enrollment target
Study Summary
Use of a microfabricated silicon device to concentrate ultra trace volatile organic compounds (VOCs) in human exhaled breath for quantitative analysis of VOCs.
Primary Outcome
The concentrated volatile organic compounds in exhaled breath samples will be analyzed by statistical software for search for disease related markers (biomarkers).
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 728 participants |
| Start Date | 2012-11-07 |
| Est. Completion | 2018-11-28 |
What the finished NCT02123030 record still lists
NCT02123030 is an observational study that tracks outcomes without assigning an intervention. The registered 728 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02123030 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02123030 about?
NCT02123030 is a clinical study titled "A Micro/Nano Device for Exhaled Breath Analysis". Use of a microfabricated silicon device to concentrate ultra trace volatile organic compounds (VOCs) in human exhaled breath for quantitative analysis of VOCs.
What is the current status of trial NCT02123030?
This trial is currently completed. The enrollment target is 728 participants. The study started on 2012-11-07. Estimated completion is 2018-11-28.
Who is sponsoring clinical trial NCT02123030?
This trial is sponsored by University of Louisville, which has 217 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05065216 · 728 participants · Phase 2
Treatment of Acute Ischemic Stroke (ReMEDy2 Trial)
- NCT05739123 · 728 participants
Relugolix Pregnancy Registry: An Observational Study of the Safety of Relugolix-Containing Therapy Exposure in Pregnant Women and Their Offspring
- NCT06433765 · 728 participants
A Study Evaluating the Effect of BRIUMVI® (Ublituximab) on Pregnancy and Infant Outcomes in Participants With Multiple Sclerosis (MS)
- NCT06660342 · 728 participants
A Study of the Safety of Vonoprazan Exposure in Pregnant Women and Their Offspring
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI